TECH
NasdaqBIO-TECHNE Corp
Basic Materials · Biological Products, (No Diagnostic Substances)
Research view
Fundamentals · SEC EDGAR · FY 2025-06-30
Revenue & Earnings — fiscal year
$931.0M
2021
$1.1B
2022
$1.1B
2023
$1.2B
2024
$1.2B
2025
Snapshot
SEC EDGAR · FY 2025-06-30Revenue$1.2B
Net Income$73.4M
Gross Profit$790.3M
Oper Income$102.3M
EPS (dil)$0.46
Rev/sh$7.79
FCF/sh$1.64
Book/sh$12.26
Gross M64.8%
Oper M8.4%
Profit M6.0%
FCF M21.0%
ROE3.8%
ROA2.9%
ROIC4.3%
R&D/Rev—
Rev Y/Y5.2%
Rev 3Y CAGR3.3%
EPS Y/Y-56.2%
EPS 3Y CAGR-34.8%
FCF 3Y CAGR-2.9%
Payout69%
Div/sh$0.32
Shs Chg Y/Y-0.7%
Current Ratio3.46
Quick Ratio2.38
Debt/Eq0.01
Int Coverage12.0×
Net Debt$149.7M cash
Total Debt$12.5M
Cash & Eq$162.2M
Total Assets$2.6B
Oper CF$287.6M
Capex$31.0M
Free CF$256.6M
Buybacks$275.7M
Equity$1.9B
Liabilities—
Shs Outstand0.16B
SectorBasic Materials
🔒 P/E—
🔒 Fwd P/E—
🔒 P/S—
🔒 P/B—
🔒 Market Cap—
🔒 Div Yield—
🔒 52W Range—
🔒 Beta—
40+ fundamentals — free from SEC EDGAR (public domain). Only the 🔒 price-derived column needs a market-data feed.
Financials — annual
SEC EDGAR · last 5 FY| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $931.0M | $1.1B | $1.1B | $1.2B | $1.2B |
| Gross Profit | $632.9M | $756.5M | $769.8M | $769.7M | $790.3M |
| Operating Income | $237.3M | $296.6M | $298.9M | $206.7M | $102.3M |
| Net Income | $139.6M | $263.1M | $285.4M | $168.1M | $73.4M |
| Diluted EPS | $0.87 | $1.66 | $1.76 | $1.05 | $0.46 |
| Operating Cash Flow | $352.2M | $325.3M | $254.4M | $299.0M | $287.6M |
| Free Cash Flow | $307.9M | $280.4M | $216.1M | $236.1M | $256.6M |
COMMUNITY · $TECH0 theses
POST YOUR TAKE →Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.